Tevogen Bio Oncology Reports Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion; Forecasts for Non-Oncology Therapeutic Areas to FollowGlobeNewsWire • 10/17/24
Tevogen Investors Congratulate on Prestigious Recognition of Pioneering Biopharma Business Model, Breakthrough Innovations, Building Assets Estimated to Exceed $10 BillionGlobeNewsWire • 10/17/24
Tevogen Bio Takes Lead in Developing Cell Therapies Designed to Eradicate Post Procedure Human Papilloma Virus in Women with Precancerous Cervical LesionsGlobeNewsWire • 10/15/24
Tevogen Bio Highlights the Publication of Promising Trial Data as the CEO Expresses Optimism About the Company's Scientific Breakthrough in Mainstreaming Cell Therapy Through a New Class of Off-the-Shelf T-Cell Therapies, Manufactured and Stored for Immediate UseGlobeNewsWire • 10/15/24
Tevogen CEO Reaffirms the Company's Commitment to Closing the Information Gap on Its Multi-Billion-Dollar Assets, Following the Release of Revenue ProjectionsGlobeNewsWire • 10/14/24
Tevogen Bio Plans to Share $1B+ Revenue Potential of its Pipeline Portfolio Beginning Week of October 14, 2024GlobeNewsWire • 10/11/24
Tevogen Bio Highlights Promising Trial Data as CEO Leads Patient Advocacy at Capitol Hill, Pledging to Leverage Multi-Billion Dollar Company Assets to Combat Long COVID and Spearhead a New Wave of Medical InnovationGlobeNewsWire • 10/08/24
Tevogen Bio Leadership Meets Members of U.S. Congress to Advocate for Long COVID Patients and Highlights Achievements and Assets as a Blueprint for Biotech InnovationGlobeNewsWire • 09/24/24
CORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewsWire • 08/15/24
Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesGlobeNewsWire • 08/15/24
Tevogen Bio's Innovation and Public Health Advisory Board Chairperson, Professor Sten Vermund, Appointed Dean of the University of South Florida Health College of Public HealthGlobeNewsWire • 08/14/24
Tevogen Bio's Founding CEO, Ryan Saadi, Expresses Conviction in Company's Growth Strategy and Reaffirms Newly Effective Form S-1 Does Not Relate to Previously Undisclosed New Issuance of Dilutive SecuritiesGlobeNewsWire • 08/09/24
Tevogen Bio Issues Letter to Stockholders Highlighting Recent Achievements, Growth Plans, and Consideration of a Potential Share BuybackGlobeNewsWire • 07/11/24
Tevogen Bio's R&D Leadership Discusses The Promise of Its Genetically Unmodified, Off-The-Shelf T Cell Technology For The Treatment of Infectious Diseases, Cancers, and Neurological Disorders With Nasdaq's Kristina AyanianGlobeNewsWire • 07/10/24
Ryan Saadi Congratulates Marc Benioff on Receiving the Yale Legend in Leadership Award and Commends Yale School of Management for Recognizing the Importance of Integrating Corporate Success with Social ResponsibilityGlobeNewsWire • 07/08/24
Tevogen Bio Files Registration Statement for Previously Disclosed Securities; Does Not Relate to Any Previously Undisclosed New Issuances of Dilutive SecuritiesGlobeNewsWire • 06/26/24
Tevogen Bio Announces Publication of Positive Phase I Clinical Trial Results for TVGN 489 in Blood AdvancesGlobeNewsWire • 06/25/24
Tevogen.AI Head Discusses Company's Bold Strategy to Shape the Future of T Cell Therapies at Longwood Spring MIT ConferenceGlobeNewsWire • 06/18/24
Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development EffortsGlobeNewsWire • 06/11/24
CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Public Listing Social Engagement EventGlobeNewsWire • 06/07/24
Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for Attending Its Inaugural Post-Listing Social Engagement EventGlobeNewsWire • 06/06/24
Tevogen Bio Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2GlobeNewsWire • 06/06/24
